Quality of Life in Renal Transplant Recipients Following Conversion From Mycophenolate Mofetil to Enteric-Coated Mycophenolate Sodium

Transplantation Proceedings

Volumn 39, Issue 7, 2007, Pages 2179-2181

  Cofan, F ^a   Rosich, E ^a   Arias, M ^a   Torregrosa, V ^a   Oppenheimer, F ^a   Campistol, J M ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ABDOMINAL DISEASE; ADULT; ARTICLE; CADAVER KIDNEY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FLATULENCE; GASTROINTESTINAL SYMPTOM; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HUMAN; KIDNEY FUNCTION; KIDNEY GRAFT; LOOSE FECES; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SOCIAL STATUS;

ADULT; CADAVER; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; QUALITY OF LIFE; TABLETS, ENTERIC-COATED; TISSUE DONORS;

EID: 34548682324     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2007.07.012     Document Type: Article

References (5)

1. Srinivas T.R., Kaplan B., Schold J.D., et al. The impact of mycophenolate mofetil on long-term outcomes in kidney transplantation. Transplantation 80 2 suppl (2005) S211
2. Pelletier R.P., Akin B., Henry M.L., et al. The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation. Clin Transplant 17 (2003) 200
3. Salvadori M., Holzer H., de Mattos A., et al. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 4 (2004) 231
4. Budde K., Knoll G., Curtis J., et al. Long-term safety and efficacy after conversion of maintenance renal transplant recipients from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPA, myfortic). Clin Nephrol 66 (2006) 103
5. Chan L., Mulgaonkar S., Walker R., et al. Patient-reported gastrointestinal symptom burden and health-related quality of life following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium. Transplantation 81 (2006) 1290